NCT01234467 - Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

August 31, 2016

Conditions

Diffuse Large B-Cell LymphomaLymphoma, Diffuse Large-CellDiffuse Large-Cell LymphomaLymphoma

Interventions

DRUG

Bendamustine

Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles

DRUG

Rituximab

Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles

Trial Locations (7)

27403

Moses Cone Regional Cancer Center, Greensboro

27599

University of North Carolina at Chapel Hill, Chapel Hill

27607

Rex Healthcare, Raleigh

27834

Leo Jenkins Cancer Center, East Carolina University Medical Center, Greenville

27889

Marion L. Shepard Cancer Center, Washington

28025

Northeast Medical Center, Concord

28607

Seby B. Jones Cancer Center, Boone